Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing^[1][2][3][4]. IC50 & Target: PKA^[1]
Phosphodiesterase (PDE)^[4] In Vitro: Both choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) mRNA increased approximately fourfold after treatment of PC12 cells with Bucladesine (dibutyryl cyclic AMP; dbcAMP). ChAT and PKA activity are also increased by Bucladesine^[5]. In Vivo: Intrahippocampal infusion of Bucladesine into the CA1 region (male Albino-Wistar rats) can cause an improvement in spatial memory in maze task. Bilateral infusion of 10 μM and 100 μM Bucladesine leads to a significant reduction in escape latency and travel distance (showing an improvement in spatial memory). Bucladesine via activation of PKA and induction of cAMP/PKA pathway improved spatial memory retention^[1].